



Berkshire West Area Prescribing Committee

Drug Name	Aliskiren (Rasilez®)		
Indication under review	Treatment of essential hypertension		
Policy No:	APC 049		
Date of Issue/ Date of reissue:	January 2014/ March 2017		
Review Date:	March 2020		
Policy Statement: Aliskiren (Rasilez®) is not recommended for the treatment of essential hypertension as it is not considered a cost effective use of scarce NHS resources.			
Traffic Light Status	Brown		
Key Points considered:			
<ul style="list-style-type: none"> • Aliskiren (Rasilez®) is significantly more expensive than other medication for treating hypertension. • There is insufficient evidence to support its use at the proposed 4th line stage of treatment. • The APC concluded that there was insufficient evidence of cost effectiveness to recommend the use of this medication. • This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget 			
References:			
<ol style="list-style-type: none"> 1. SMC information available via http://www.scottishmedicines.org.uk/smc/6378.html 2. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD007066. 			
Date taken to APC:	1 st March 2017		
Date Ratified by GP MOC on Behalf of Board:	15 th March 2017		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only